老年套细胞淋巴瘤研究进展  

Research Progress of Mantle Cell Lymphoma in the Elderly Patient

作　　者：余长艳[1] 周雪萌 赵曙[1] 张悦[1] 张清媛[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《中国肿瘤》2016年第9期715-720,共6页China Cancer

基　　金：国家自然科学基金(81101703)

摘　　要：套细胞淋巴瘤（mantle cell lymphoma,MCL）是一种独特的B细胞淋巴瘤,占非霍奇金淋巴瘤（non-Hodgkin’s lymphoma,NHL）的3%-10%,除自体干细胞移植（ASCT）外,MCL无其它可治愈的手段。MCL多见于老年男性,多数老年患者常合并基础疾病而不能耐受大剂量化疗和ASCT。全文主要分析MCL的病理生理、治疗、风险分层、预后以及老年患者的治疗选择。Mantle cell lymphoma （MCL） is a relatively rare B-cell lymphoma,accounted for about 3%-10% of all non-Hodgkin＇s lymphoma （NHL）. There is no curative treatment,except allogeneic stem cell transplantation （ASCT） for patients with MCL. However,the majority patient of MCL is elderly men, and often accompanied with underlying diseases cannot tolerate high-dose chemother- apy and ASCT. The histological type, staging,risk stratification,prognosis and the treatment selec- tion for elderly of MCL were analyzed in this article.

关 键 词：套细胞淋巴瘤 化学免疫治疗 老年患者 

分 类 号：R733[医药卫生—肿瘤]